Compare Adaptive Biotechnologies Corp (ADPT) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Financial Select Sector SPDR Fund — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Financial Select Sector SPDR Fund trades at $55.2. Which is the better fit depends on your goals.
| ADPT | XLF | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | — |
52-Week High | $22.37 | $56.41 |
52-Week Low | $10.24 | $47.80 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
XLF trades at $56.15, up 0.95% with strong technical momentum as moving averages signal bullish alignment. The ETF faces pivotal Q2 earnings season with major bank components reporting, while regulatory developments and potential rate hikes create both opportunities and headwinds. Recent Federal Reserve stress test results have enabled increased dividends, with XLF announcing a $0.19 dividend for H1-2026.
The financial sector ETF shows technical strength but faces fundamental tests from earnings season and regulatory uncertainty. Upside potential exists from dividend growth and potential rate hike benefits, while risks include AI cybersecurity threats and election-driven market volatility that could pressure financial stocks in H2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
